Genomic alterations of primary tumor and blood in invasive ductal carcinoma of breast

World Journal of Surgical Oncology

Research

Jin Soo Choi¹  Seung Ho Baik¹  Young Lim²  Woo Chan Park³  Byung Joo Song³  Sang Seol Jung³  Jeong Soo Kim³  Ja Seong Bae³ 

[1] Catholic Neuroscience Center, The Catholic University, Seoul, Korea;Department of Occupational and Environmental Medicine, St. Mary's Hospital, The Catholic University, Seoul, Korea;Department of Surgery, The Catholic University, Seoul, Korea;

关键词: Real Time Polymerase Chain Reaction;    Comparative Genomic Hybridization;    Array Comparative Genomic Hybridization;    Copy Number Gain;    Copy Number Loss;   

DOI  :  10.1186/1477-7819-8-32

 received in 2009-12-26, accepted in 2010-04-21,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundGenomic alterations are important events in the origin and progression of various cancers, with DNA copy number changes associated with progression and treatment response in cancer. Array CGH is potentially useful in the identification of genomic alterations from primary tumor and blood in breast cancer patients. The aim of our study was to compare differences of DNA copy number changes in blood and tumor tissue in breast cancer.MethodsDNA copy number changes in blood were compared to those in tumor tissue using array-comparative genomic hybridization in samples obtained from 30 breast cancer patients. The relative degree of chromosomal changes was analyzed using log2 ratios and data was validated by real-time polymerase chain reaction.ResultsForty-six regions of gains present in more than 30% of the tissues and 70 regions of gains present in more than 30% of blood were identified. The most frequently gained region was chromosome 8q24. In total, agreement of DNA copy numbers between primary tumor and blood was minimal (Kappa = 0.138, p < 0.001).ConclusionAlthough there was only a slight agreement of DNA copy number alterations between the primary tumor and the blood samples, the blood cell copy number variation may have some clinical significance as compared to the primary tumor in IDC breast cancer patients.

【 授权许可】

Unknown   
© Bae et al; licensee BioMed Central Ltd. 2010. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.